Acumen Pharmaceuticals (NASDAQ: ABOS) insider plans 1,700-share Rule 144 sale

Rhea-AI Filing Summary

Acumen Pharmaceuticals insider plans a small stock sale under Rule 144. The filing reports an intended sale of 1,700 shares of common stock through Merrill Lynch on or around 01/07/2026 on NASDAQ. The shares were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted under the company’s equity compensation plan.

The notice also lists recent activity: the same seller disposed of 4,000 common shares on 01/05/2026 for gross proceeds of $7,832.50, and 3,618 shares on 01/06/2026 for gross proceeds of $7,114.46. The filing indicates there are 60,573,425 common shares outstanding. The person on whose behalf the shares are being sold represents that they are not aware of undisclosed material adverse information about Acumen’s operations.

Insights

Insider transactions analyst

Routine Rule 144 sale of recently vested equity, modest versus shares outstanding.

The notice describes an intended sale of 1,700 Acumen Pharmaceuticals common shares, acquired the prior day via vesting of a restricted stock unit award under the equity plan. This aligns with typical insider liquidity from stock-based compensation rather than a large discretionary position change.

The seller also reported two recent sales totaling 7,618 shares over the prior two days, for gross proceeds of $7,832.50 and $7,114.46. With common shares outstanding of 60,573,425, these amounts are small relative to the overall share base. The representation that the seller is unaware of undisclosed material adverse information is standard language for such notices.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	1700	3378.00	60573425	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/06/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			1700	01/06/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Russell Barton 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7832.50
Russell Barton 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	3618	7114.46

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Acumen Pharmaceuticals (ABOS) shares are planned to be sold?

The filing states an intended sale of 1,700 shares of Acumen Pharmaceuticals common stock through Merrill Lynch.

How were the Acumen Pharmaceuticals (ABOS) shares being sold acquired?

The 1,700 shares were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted under Acumen’s equity compensation plan.

What recent Acumen Pharmaceuticals (ABOS) stock sales has the insider made?

The seller reported selling 4,000 common shares on 01/05/2026 for $7,832.50 and 3,618 shares on 01/06/2026 for $7,114.46.

On which exchange will the Acumen Pharmaceuticals (ABOS) shares be sold?

The notice identifies NASDAQ as the securities exchange for the planned sale of Acumen Pharmaceuticals common stock.

How many Acumen Pharmaceuticals (ABOS) shares are outstanding?

The filing lists 60,573,425 shares of Acumen Pharmaceuticals common stock as outstanding.

Does the insider claim to know any undisclosed negative information about Acumen Pharmaceuticals (ABOS)?

No. By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about Acumen’s current or prospective operations that has not been publicly disclosed.